Posted by psychobot5000 on September 28, 2006, at 23:38:04
In reply to buspar properties; gepirone available anywhere?, posted by iforgotmypassword on September 25, 2006, at 15:50:39
I have heard no new news, but the word was, last time I heard, that the FDA had rejected gepirone applications, and the rationale for reapplying seemed poor.
However, a 5HT-1a agonist of another sort, PRX-00023 recently finished (sept 21 06) a stage 3 trial for GAD. Possibly due in part to larger-than-expected placebo response, the study failed to show a statistically significant trend in favor of prx-00023, though an insignificant one was there. BUT...
The secondary goal of the study showed positive results (statistically significant, too) for patient ratings on the MADRS scale. So it seems to be effective for depression--it is in phase 2 for depression, and the developer plans to regear development toward that indication. It is likely to be better tolerated, with fewer side-effects, than the buspirone-type meds. We may see it on the market in a year or two.
http://news.pajamasmedia.com/health/2006/09/21/10962844_EPIX_Pharmaceuti.shtml
poster:psychobot5000
thread:689124
URL: http://www.dr-bob.org/babble/20060927/msgs/690094.html